Breaking News, Financial News

Financial Report: Novartis 4Q

Pharmaceutical sales were $6.4 billion in the quarter (+5%) and $26.3 billion for the year (+10%), driven by growth in oncology, the cardiovascular portfolio and $2.9 billion of contributions from recently launched products including Aclasta/Reclast, Tekt

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novartis   4Q Revenues: $10.1 billion (+1%)   4Q Earnings: $1.5 billion (+62%)   FY Revenues: $41.5 billion (+9%)   FY Earnings: $8.2 billion (+25%)   Comments: Pharmaceutical sales were $6.4 billion in the quarter (+5%) and $26.3 billion for the year (+10%), driven by growth in oncology, the cardiovascular portfolio and $2.9 billion of contributions from recently launched products including Aclasta/Reclast, Tekturna/Rasilez, Exforge, Exjade, Lucentis, Exelon Patch, Tasigna and Xolair...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters